Predicting survival and leukemic evolution in patients with myelodysplastic syndrome.
2006; National Institutes of Health; Volume: 91; Issue: 12 Linguagem: Inglês
Autores
Luca Malcovati, Matteo Giovanni Della Porta, Mario Cazzola,
Tópico(s)Retinoids in leukemia and cellular processes
ResumoThe impressive heterogeneity of the natural history of MDS, ranging from indolent condi tions with near normal life expectancy to forms rapidly progressing to leukemia, complicates clinical decisionmaking regarding therapeutic modalities and timing of interventions. 3 In 1982, the French-American British (FAB) co-opera tive group proposed a classification of MDS based on morphological criteria. 4 For the following 20 years this classification represented the benchmark for clinical management and investigational studies in MDS. However, considerable heterogeneity was observed within FAB subgroups, raising the need for prognostic systems with a better ability to predict survival and leukemic progression in MDS patients. Various prog nostic models were proposed based on demographic and disease-related variables, including age, peripheral cytopenias, bone marrow blast count, lactate dehydro genase level and karyotypic abnormalities. 5,6
Referência(s)